Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sonnet Biotherapeutics Holdings Inc (NQ: SONN ) 0.8564 -0.0036 (-0.42%) Streaming Delayed Price Updated: 3:58 PM EDT, Jul 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Sonnet Biotherapeutics Holdings Inc < Previous 1 2 3 Next > InvestorNewsBreaks – Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) Releases Pricing of Underwritten Public Offering to Total Estimated $15M February 14, 2023 Via Investor Brand Network Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update February 13, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering February 08, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates February 01, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update August 15, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010 January 19, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer January 09, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update December 15, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010 November 02, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022 November 01, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates October 31, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement October 04, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee September 26, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010 September 21, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split September 16, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy July 22, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy July 22, 2022 PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers July 21, 2022 Via ACCESSWIRE Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers July 21, 2022 PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition June 09, 2022 PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum June 02, 2022 PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update May 10, 2022 - IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors - SON-080 on track to begin clinical studies by mid-2022 - Preclinical data for SON-1010, SON-1210, and... From Sonnet BioTherapeutics, Inc. Via AccessWire Exposures Product Safety Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors April 13, 2022 PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting April 08, 2022 PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors March 16, 2022 - Represents Sonnet's first IND cleared - Phase 1 trial initiation expected in 2Q22 PRINCETON, NJ / ACCESSWIRE / March 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the... From Sonnet BioTherapeutics, Inc. Via AccessWire Exposures Product Safety Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting February 09, 2022 PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update February 08, 2022 - SON-1010 and SON-080 on track to initiate clinical studies during the second quarter of 2022 - Completed R&D manufacturing for SON-1210 non-GLP toxicity study in non-human primates, with study... From Sonnet BioTherapeutics, Inc. Via AccessWire Exposures Product Safety Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update December 17, 2021 PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) August 30, 2021 - SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs - Selection of the... From Sonnet BioTherapeutics, Inc. Via AccessWire Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering August 19, 2021 PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic... From Sonnet BioTherapeutics, Inc. Via AccessWire Topics Regulatory Compliance Exposures Legal Regulatory < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.